Pfizer Inc. recalled 29,004 bottles of Levoxyl on July 29, 2025, due to subpotency. The recall affects levothyroxine sodium tablets, 50 mcg, Rx only, distributed in the U.S. Consumers should stop using the product immediately.
Subpotent drug
Consumers and healthcare providers should stop using this product immediately. Contact Pfizer or your healthcare provider for guidance. Notification method: Letter
The recall involves Levoxyl (levothyroxine sodium tablets, USP), 50 mcg, in 100-count bottles. The lot number is 24C11, and it expires on February 28, 2026.
Levoxyl may not contain the intended potency of levothyroxine sodium, which can lead to insufficient thyroid hormone levels. This is classified as a Class II recall, indicating a potential for temporary health issues.
No specific incidents or injuries have been reported related to this recall. The risk remains high due to the potential for untreated thyroid conditions.
Stop using Levoxyl immediately. Contact your healthcare provider for further guidance and instructions on returning the product.
For questions, call Pfizer at 1-800-XXX-XXXX or visit their website at www.pfizer.com. Additional recall information is available through the FDA.
Glenmark Pharmaceuticals Inc. recalled 13,824 tubes of Azelaic Acid Gel on September 17, 2025. The recall stems from market complaints regarding a gritty texture. Consumers should stop using the product immediately and contact their healthcare provider.
Skin MD by Dr Monika Kiripolsky recalled its Body Acne Cleanser on September 12, 2025. The recall follows the discovery of elevated benzene levels in the product. This contamination poses a high health risk to consumers in California and Georgia.
Private Label Skin Care recalled its Micronized BPO Gel Cleanser 10% on September 12, 2025. Elevated benzene levels prompted the recall in California and Georgia. Consumers must stop using the product immediately and seek guidance from healthcare providers.